GHRP-2: what it is and what the evidence says
A releasing hexapeptide that activates the ghrelin receptor and triggers a potent, reproducible pulse of growth hormone, with less effect on appetite than GHRP-6. In Japan it is employed, under the name pralmorelin, as a diagnostic test of the GH axis.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Hormones work in axes: a signal from the brain tells a gland to release another hormone, and so on down the chain, with brakes that shut the process off. Intervening at one point has consequences both upstream and downstream. That is why this is the group where professional assessment stops being a recommendation and becomes essential.
What it is studied for
Recovery, body composition.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
It is the peptide secretagogue with the most human data. There is a diagnostic test approved in Japan, with more than 500 patients in post-approval surveillance, studies of increased food intake in adults, a one-month subcutaneous infusion study in older adults with sustained IGF-1, and long-term studies in children by the subcutaneous, intranasal, and oral routes.
The limitation that matters most
Its validated role is diagnostic, with a single injection. There are still no trials measuring body composition, strength, or performance in healthy adults, and no safety data on repeated use over months; it increases appetite and transiently raises ACTH, cortisol, and prolactin.
Regulatory status
In Japan it has been approved since 2004 as a diagnostic test for growth hormone deficiency (pralmorelin). No agency has approved it as a treatment, and in the United States the FDA does not include it among the substances for pharmacy compounding. In sport, WADA prohibits it at all times under section S2, where it is listed by name.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
It increases appetite and transiently raises ACTH, cortisol, and prolactin, so those hormones are tracked along with IGF-1, glucose, and waist. For anyone who competes, WADA names it in section S2.
With a pituitary adenoma, high prolactin, diabetes or prediabetes, pregnancy or breastfeeding, or if you compete under anti-doping control, have a professional assess it before you start and while you are on it.
What this page cannot give you
A reference page can take you this far. You know what GHRP-2 is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a Certificate of Completion with a verifiable certificate ID, a Progress Tracker to follow how you are doing, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humanshuman J Pediatr Endocrinol Metab · 1996 · PMID 8887169 →
- Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient childrenhuman J Pediatr Endocrinol Metab · 2003 · PMID 14513874 →
- Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy menhuman J Clin Endocrinol Metab · 2005 · PMID 15699539 →
- Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadismhuman Eur J Endocrinol · 2009 · PMID 19458139 →
- Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorderhuman J Endocr Soc · 2022 · PMID 35795807 →
- Robust growth hormone responses to GH-releasing peptide 2 in adolescentshuman J Pediatr Endocrinol Metab · 2024 · PMID 38958228 →
- Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short staturehuman Metabolism · 1995 · PMID 7666796 →
- Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LNreview Drugs R D · 2004 · PMID 15230633 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for GHRP-2 or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is GHRP-2?
A releasing hexapeptide that activates the ghrelin receptor and triggers a potent, reproducible pulse of growth hormone, with less effect on appetite than GHRP-6. In Japan it is employed, under the name pralmorelin, as a diagnostic test of the GH axis. It is studied within the area of hormonal/sexual.
Is there human evidence for GHRP-2?
It is the peptide secretagogue with the most human data. There is a diagnostic test approved in Japan, with more than 500 patients in post-approval surveillance, studies of increased food intake in adults, a one-month subcutaneous infusion study in older adults with sustained IGF-1, and long-term studies in children by the subcutaneous, intranasal, and oral routes.
Is it approved by any health agency?
In Japan it has been approved since 2004 as a diagnostic test for growth hormone deficiency (pralmorelin). No agency has approved it as a treatment, and in the United States the FDA does not include it among the substances for pharmacy compounding. In sport, WADA prohibits it at all times under section S2, where it is listed by name.
What is the dose of GHRP-2?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what GHRP-2 is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.